Sugi Predict

Sugi Predict / Compounds / SCHEMBL1108465

SCHEMBL1108465

SCHEMBL1108465

COc1cc(N)ccc1OCC1(C)NC(=O)NC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NR4A1 P22736 1/20 0.38
▸ ADAM17 P78536 8/20 0.38
▸ MMP1 P03956 1/20 0.38
▸ MMP2 P08253 1/20 0.38
▸ MMP3 P08254 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ MMP14 P50281 1/20 0.38
▸ ADAM9 Q13443 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ CYP19A1 P11511 1/20 0.36
▸ ADAMTS5 Q9UNA0 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1108498 0.82 SMN1; SMN2 (0.47) SMN1; SMN2NPSR1ADAM17MMP1MMP2
SCHEMBL1108460 0.79 SMN1; SMN2 (0.42) SMN1; SMN2NPSR1ADAM17MMP1MMP2
SCHEMBL2893907 0.72 SMN1; SMN2 (0.52) KDM4ESMN1; SMN2NPSR1ADAM17MMP1
SCHEMBL1159205 0.68 GAA (0.96) GAAMAPTKDM4ESMN1; SMN2TSHR
SCHEMBL1108471 0.68 ALDH1A1 (0.52) GAAMAPTSMN1; SMN2NPSR1ADAM17
SCHEMBL29377777 0.67 KDM4E (0.67) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL2438047 0.67 KDM4E (0.67) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL77823 0.67 KDM4E (0.67) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL27943504 0.67 GAA (0.68) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL12378824 0.66 SMN1; SMN2 (0.48) SMN1; SMN2NPSR1ADAM17MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 — — US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 — — US disclosed
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
EP-1676846-B1 Hydantoin derivatives as MMP inhibitors ASTRAZENECA AB (SE) 2010-12-29 — — EP disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 — — US disclosed
EP-1370537-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2010-10-13 — — EP disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 — — US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 — — US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 — — US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 — — US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 — — US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 — — US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003853-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 GAA 123/4885MAPT 3422/4885KDM4E 1736/4885
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 GAA 271/4885MAPT 4661/4885KDM4E 2253/4885
US-20080171882-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 GAA 123/4885MAPT 3422/4885KDM4E 1736/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 GAA 271/4885MAPT 4661/4885KDM4E 2253/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 GAA 296/4885MAPT 4705/4885KDM4E 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.